WEBINAR: Clinical Trials for, and despite, COVID-19
ABSTRACT: The current SARS-CoV-2-induced coronavirus 2019 (COVID-19) pandemic has called for urgent design and implementation of clinical trials against this potentially life-threatening infection. The pandemic has also had a tremendous impact on ongoing clinical trials for all other indications. In both cases, the crisis has highlighted several limitations that currently exist and hinder a more agile and pragmatic, but at the same time ethically and scientifically sound, clinical-trials enterprise.
Marc Buyse, ScD, Chief Scientific Officer at IDDI.
- He holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA).
- He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe.
- He is interested in clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing (http://publicationslist.org/marc.buyse).
Everardo Saad, MD: Medical Director at IDDI
- He has nearly 20 years of experience in Medical Oncology and clinical trial designs.
- He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston.
- After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.